Clin Asst Prof Zhang Zewen

Dr Zhang Zewen is a Medical Oncologist in NCCS sub-specialising in Breast cancer and Gynecological cancer. He is part of the Cancer Genetics Service team involved in research related to hereditary cancer predisposition syndromes, including Hereditary Breast and Ovarian Cancer and Lynch syndrome. In addition, he also serves as educator in both Duke-NUS Graduate Medical School and Yong Loo Lin School of Medicine, and is active in teaching for medical students, registrars and nurses. Following receipt of the Ministry of Health–SingHealth Health Manpower Development Plan Award in 2025, he completed fellowship training in Hereditary Breast and Ovarian Cancer at Manchester Centre for Genomic Medicine in 2026.

• Member of Royal College of Physicians (Edinburgh); Master of Medicine (Internal Medicine) (Singapore), 2016 
• Duke-NUS Graduate Medical School, Doctor of Medicine (MD), 2013 
• 1st Class Honors, Bachelor’s degree, NUS Chemical Engineering, 2009

• Committee Member of the Pharmaceutical Society of Singapore (PSS)
• Institution Committee of Advanced Practice Nurse (APN) Competence (CAC), 2023 to current 
• IBRCA Forum Co-Chair, 2022 to current

• Ministry of Health-SingHealth Health Manpower Development Plan Award Fellowship, Manchester Centre for Genomic Medicine, 2025
• SingHealth Quality Service Award Gold, 2025
• Academic Clinical Programme (ACP) Programme Grants, Oncology, Education support, 2024 
• Outstanding Resident Award (RISE), Medical Oncology, 2018 
• SingHealth Seah Cheng Siang Gold Medal in Medicine, Duke-NUS Graduate Medical School, 2013 
• Duke-NUS Humanism Award, Duke-NUS Graduate Medical School, 2013 
• Singapore Medical Association-Lee Foundation Teamsmanship Award, Duke-NUS Graduate Medical School, 2013

• Yuen J, Zhou S, Caeser R, Venkatramani M, Bte Ishak DN, Li ST, Zhang Z, Chiang J, Chan SH, Ngeow J. Multi-locus inherited neoplasia alleles syndromes in cancer: implications for clinical practice. Eur J Hum Genet. 2025 Mar
• Lim A, Chua ZY, Loh C, Suresh PD, Yuen J, Kartikeyan M, Zewen Z, Chiang J, Koh MJA, Fong NWY, Tan ES, Ngeow J. Identifying the unmet needs of patients with neurofibromatosis type 1 in Singapore. J Med Genet. 2025 Aug 
• Que FVF, Ishak NDB, Li ST, Yuen J, Shaw T, Goh HX, Zhang Z, Chiang J, Yeo SY, Chew LL, Thng CH, Ngeow J. Utility of Whole-Body Magnetic Resonance Imaging Surveillance in Children and Adults With Cancer Predisposition Syndromes: A Retrospective Study. JCO Precis Oncol. 2025 Mar
• Chan JY, Zhang Z, Chew W, Tan GF, Lim CL, Zhou L, Goh WL, Poon E, Somasundaram N, Selvarajan S, Sittampalam K, Chin F, Teh J, Tan MH, Soo KC, Teo M, Farid M, Quek R. Biological significance and prognostic relevance of peripheral blood neutrophil-to-lymphocyte ratio in soft tissue sarcoma. Sci Rep. 2018 Aug 
• Qi TH, Hian OH, Kumaran AM, Tan TJ, Cong TRY, Su-Xin GL, Lim EH, Ng R, Yeo MCR, Tching FLLW, Zewen Z, Hui CYS, Xin WR, Ooi SKG, Leong LCH, Tan SM, Preetha M, Sim Y, Tan VKM, Yeong J, Yong WF, Cai Y, Nei WL; JBCR; Ai3. Multi-center evaluation of artificial intelligent imaging and clinical models for predicting neoadjuvant chemotherapy response in breast cancer. Breast Cancer Res Treat. 2022 May
• Zhang Z, Ishak NDB, Que FVF, Chua ZY, Chan SH, Chiang J, Yie JNY. COVID-19 vaccination uptake and safety profile among germline BRCA1 and BRCA2 pathogenic variant carriers in Singapore. Hered Cancer Clin Pract. 2023 Apr
• Liew SZH, Ng KW, Ishak NDB, Lee SY, Zhang Z, Chiang J, Ngeow JYY. Geographical, ethnic, and genetic differences in pancreatic cancer predisposition. Chin Clin Oncol. 2023 Jun
• Ishak ND, Shaw T, Li ST, Yuen J, Goh HX, Chua ZY, Suresh P, Que FVF, Zhang Z, Chiang J, Ngeow J. Cancer patients' experience of receiving variant of uncertain significance results: An Asian perspective. J Genet Couns. 2023 Oct 
• Ho WK, Hassan NT, Yoon SY, Yang X, Lim JMC, Binte Ishak ND, Ho PJ, Wijaya EA, Ng PP, Luccarini C, Allen J, Tai MC, Chiang J, Zhang Z, See MH, Thong MK, Woo YL, Dunning AM, Hartman M, Yip CH, Mohd Taib NA, Easton DF, Li J, Ngeow J, Antoniou AC, Teo SH. Age-specific breast and ovarian cancer risks associated with germline BRCA1 or BRCA2 pathogenic variants - an Asian study of 572 families. Lancet Reg Health West Pac. 2024 Feb 
• Ngoi NYL, Lee JY, Lim D, Thian YL, Lim YW, Chan JJ, Chay WY, Zhang Z, Gopinathan A, Lim SE, Low J, Ng J, Tong P, Lee YJ, Park J, Kim JW, Tan TZ, Zhu J, Tai BC, Choi CH, Kim BG, Tan DSP. Pembrolizumab plus lenvatinib in recurrent gynaecological clear cell carcinoma (LARA): a multicentre, single-arm, phase 2 trial. Lancet Oncol. 2026 Jan 
• Yuen J, Li ST, Courtney EK, Karthikeyan M, Scriven T, Binte Ishak ND, Goh HX, Lim T, Zhang Z, Chiang J, Kanesvaran R, Dent R, Ngeow J. Inefficiencies in precision medicine: can genetic counsellors (GC) be the solution? The experience from the first GC-led cancer genetics service in Asia. J Med Genet. 2025 Nov 
• Tan A, Wang W, Long C, Zhang Z, Ngeow J, Mattar C. Pregnancy-associated breast cancer: Management of the mother, fetus and tumour. Ann Acad Med Singap. 2025 Apr 
• Tan JZC, Zhang Z, Goh HX, Ngeow J. BRCA and Beyond: Impact on Therapeutic Choices Across Cancer. Cancers (Basel). 2024 Dec